MRVL.V - Marvel Biosciences Corp.
| Previous Close | 0.0950 |
| Open | 0.0950 |
| Bid | 0.0900 x N/A |
| Ask | 0.1000 x N/A |
| Day's Range | 0.0950 - 0.0950 |
| 52 Week Range | 0.0750 - 0.1700 |
| Volume | |
| Avg. Volume | 17,133 |
| Market Cap | 3.78M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0400 |
| Earnings Date | Mar 30, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Baystreet
Stocks in play: Marvel Biosciences Corp
Announces that along with its wholly owned subsidiary, Marvel Biotechnology Inc., it has completed the ...
NewsfileMarvel Successfully Completes the Dog and Rat GLP Toxicology Studies Required to Enter Human Trials
Calgary, Alberta--(Newsfile Corp. - April 20, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has completed the dosing portion of the 4-week good laboratory practice (GLP) FDA investigational new drug (IND) enabling dose-ranging dog and rat studies for its lead drug candidate MB-204."We are pleased to report we have now completed treating both rats and dogs ...
NewsfileMarvel Commences Final Study Required Prior to Initiating Human Trials
Calgary, Alberta--(Newsfile Corp. - March 21, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has initiated the 4-week good laboratory practice (GLP) FDA investigational new drug (IND) enabling dose-ranging dog studies for its lead drug candidate MB-204."This dog study is the last of the two key primary animal studies we need to complete before entering phase ...
NewsfileMarvel Biosciences Initiates Four Week Rat GLP Toxicology Study
Calgary, Alberta--(Newsfile Corp. - March 9, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has initiated the 4-week good laboratory practice (GLP) FDA investigational new drug (IND) enabling dose-ranging rat studies for its lead drug candidate MB-204."This rat study, along with the GLP study on dogs, are the last two key studies we need to complete ...
NewsfileMarvel Biosciences Announces Closing of First Tranche of Debenture Offering
Calgary, Alberta--(Newsfile Corp. - February 24, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) ("Marvel" or the "Corporation") announced today that it has completed the closing of the first tranche of the previously announced non-brokered private placement of debentures ("Debentures") for gross proceeds of $1,000,000 (the "Private Placement"), subject to final approval of the TSX Venture Exchange.The Debentures bear interest at the rate of eight percent (8%) per annum, payable annually and matur
NewsfileMarvel Biosciences Announces Proposed Debenture Offering
Calgary, Alberta--(Newsfile Corp. - February 15, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) ("Marvel" or the "Company") announced today its intention to complete a non-brokered private placement offering of unsecured convertible debentures ("Debentures") in the principal amount of up to $1,500,000 (the "Private Placement"). The Debentures will bear interest at the rate of eight percent (8%) per annum, payable annually and will mature on the date that is three years from the closing date. ...
NewsfileMarvel Biosciences Completes a Critical Manufacturing Milestone Required to Enter Phase 1 Human Trials Targeting Alzheimer's Disease and Depression
Calgary, Alberta--(Newsfile Corp. - January 6, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company " or "Marvel "), are pleased to announce that it has successfully completed a multi-kilogram scale run under current good manufacturing practices ("cGMP") of the active pharmaceutical ingredient (API) of the Company's lead asset MB-204 in partnership with Zhejiang Ausun Pharmaceutical Co., Ltd. ("Ausun"). The cGMP mater
NewsfileMarvel Biosciences Successfully Completes its Short Term Dose Ranging Study in Rats and Dogs for MB-204
Calgary, Alberta--(Newsfile Corp. - January 3, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has successfully completed its dose-ranging toxicology studies in rats and dogs, for its lead drug candidate MB-204. These studies will assist in determining the doses for the IND-enabling 4-week GLP toxicology studies."We are looking forward to initiating the 4-week toxicol
NewsfileMarvel Biosciences Announces Letter Agreement for Market Stabilization and Liquidity Services
Calgary, Alberta--(Newsfile Corp. - December 23, 2022) - Marvel Biosciences Inc. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has entered into a Letter Agreement for Market Stabilization and Liquidity Services (the "Consulting Agreement") with Mr. Adam Smith of Red Cloud Securities Inc. ("Red Cloud") to support Marvel's market stabilization and liquidity activities.Marvel entered into the Consulti
NewsfileMarvel Biosciences Announces Stock Option Grant
Calgary, Alberta--(Newsfile Corp. - December 20, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today announced that its board of directors has approved the grant of incentive stock options (the "Options") to a director to acquire 200,000 common shares in the capital of the Company at an exercise price of $0.135 being the closing price of the Company's common shares on the ...
NewsfileMarvel Biosciences Initiates Its Final FDA-Required Experiment Prior to Initiating Human Trials for Its Lead Drug Candidate MB-204
Calgary, Alberta--(Newsfile Corp. - December 12, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces it has initiated its 10-day, dose-ranging toxicology study, using dogs, for its lead drug candidate MB-204.To date, the Company's MB-204 has shown positive and promising data addressing depression, anxiety as well as its potential benefit in protecting patient's vital organs while going throug
NewsfileMarvel Biosciences Initiates the Next Milestone Study for its Lead Asset MB-204 Targeting Alzheimer's and Depression
Calgary, Alberta--(Newsfile Corp. - December 7, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has initiated its 7-day dose-ranging, toxicology study, using rats, for its lead molecule MB-204. This is a vital step in preparation to initiate FDA Phase I human clinical trials."We have significantly de-risked the development of our lead drug candidate MB-204 and have ..
NewsfileMarvel Biosciences Announces Director Appointment and Resignation
Calgary, Alberta--(Newsfile Corp. - November 24, 2022) - Marvel Biosciences Inc. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that, effective November 23, 2022, Mr. Babak Pedram has joined its Board of Directors.Babak Pedram, DirectorMr. Pedram brings a vast degree of business, capital markets and scientific experience to Marvel's Board of Directors. He is a seasoned capital market professional with over
NewsfileMarvel Biosciences' Lead Drug Candidate MB-204 Demonstrates a 400% Increase in the Survival Rate of Animals Treated with a High Dose of the Cancer Treatment Cis-Platinum
Calgary, Alberta--(Newsfile Corp. - November 22, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that in a recent study done by the Company, its lead drug candidate MB-204 demonstrated a 400% increase in the survival rate of animals being treated by high doses of chemotherapy treatment, cis-platinum."We are seeing great momentum being built around our lead drug candidate ...
NewsfileMarvel Biosciences Lead Drug Candidate MB-204 Demonstrated Superior Anti-Anxiety Activity over FDA-Approved Istradefylline in Head-To-Head Pre-Clinical Studies
Calgary, Alberta--(Newsfile Corp. - November 14, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that in a pre-clinical test for anxiety, its lead drug candidate MB-204, a fluorinated derivative of Istradefylline, out-performed Istradefylline in a head-to-head pre-clinical and in depressive and anti-anxiety studies. Istradefylline is the only US FDA approved A2a receptor anta
NewsfileMarvel Biosciences' Lead Drug Candidate MB-204 Successfully Targets Brain Receptor Important for Alzheimer's Disease and Depression
Calgary, Alberta--(Newsfile Corp. - November 7, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announced today that in a pre-clinical mouse study conducted by the Company, its lead drug candidate MB-204 successfully entered the brain and occupied its target, the adenosine A2a receptor. The adenosine A2a receptor has been validated by numerous scientific studies that it plays a significant role in
NewsfileMarvel Biosciences Successfully Completes Engineering Run of Its Lead Asset Targeting Alzheimer's Further Advancing Towards FDA Phase I Human Trials
Calgary, Alberta--(Newsfile Corp. - November 1, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces it has successfully completed a large-scale engineering run of its novel solid amorphous dispersion (SAD) formulation of MB-204 by Zhejiang Ausun Pharmaceutical Co., Ltd. ("Ausun"). The engineering run material will be utilized to support the ongoing toxicology studies of MB-204 being conducted
NewsfileMarvel Biosciences Advances Closer to Human Trials After the Successful Completion of a Second Maximum Tolerated Dose Study, a Critical Milestone Towards FDA Clinical Studies
Calgary, Alberta--(Newsfile Corp. - October 25, 2022) - Marvel Biosciences Inc. (TSXV: MRVL) (the "Company" or "Marvel") is pleased to announce it has completed its maximum tolerated dose (MTD) toxicology study in dogs for its product MB-204, further validating the Company's lead drug candidate low toxicity characteristic. "We have now completed and further validated MB-204's safety profile through this recent dog toxicology study in addition to our recently press released toxicology study in ra
NewsfileMarvel Biosciences Successfully Completes Maximum Tolerated Dose Study, a Critical Milestone Towards FDA Clinical Studies
Calgary, Alberta--(Newsfile Corp. - October 17, 2022) - Marvel Biosciences Inc. (TSXV: MRVL) (the "Company" or "Marvel") is pleased to announce it has completed its maximum tolerated dose (MTD) toxicology study for its product MB-204, validating its low toxicity.MB-204 is the Company's lead compound and is a novel fluorinated form of Istradefylline (FDA approved anti-Parkinson's disease drug) and is a blood brain barrier permeable adenosine A2a receptor antagonist. Marvel is developing MB-204 fo
NewsfileMarvel Biosciences Highlights Recent Research on the Serotonin Theory of Depression
Calgary, Alberta--(Newsfile Corp. - October 4, 2022) - Marvel Biosciences Inc. (TSXV: MRVL) (the "Company" or "Marvel") highlights recent a meta-analysis which re-evaluated the strength of the link between serotonin levels and depression. According to the study published in Nature Molecular Psychiatry on July 20, 2022 1, despite the influence of the serotonin theory of depression, there was no comprehensive review of the scientific literature undertaken, despite the various known facts of the pa
NewsfileMarvel Biosciences Announces Stock Option Grants
Calgary, Alberta--(Newsfile Corp. - September 26, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today announced that its board of directors has approved the grant of incentive stock options (the "Options") to certain directors and officers to acquire an aggregate of 1,425,000 common shares in the capital of the Company at an exercise price of $0.10, which is above the closing price ...
NewsfileMarvel Biosciences Highlights Recent Research on Link Between NASH and Alzheimer's Disease
Calgary, Alberta--(Newsfile Corp. - August 31, 2022) - Marvel Biosciences Inc. (TSXV: MRVL) (the "Company" or "Marvel") highlights recent research indicating a link between non-alcoholic steatohepatitis (NASH) and Alzheimer's Disease (AD), two programs its lead asset, MB-204 are targeting.A five-year longitudinal study in Sweden tracked subjects with and without NASH over the age of 65, and those with NASH had a 38% higher risk of developing dementia(1). With up to 25% of the population ...
NewsfileMarvel Biosciences Closes Second Tranche of Private Placement
Calgary, Alberta--(Newsfile Corp. - August 9, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to report that, further to its news releases of June 21, 2022 and July 18, 2022, it has closed its non-brokered private placement of 7,200,000 units of the Company (the "Units") at a price of $0.10 per Unit for aggregate gross proceeds of $720,000 (the "Offering"). ...
NewsfileMarvel Announces Identification of a Novel Formulation of Its MB-204 Asset
Calgary, Alberta--(Newsfile Corp. - July 21, 2022) - Marvel Biosciences Inc. (TSXV: MRVL) (the "Company" or "Marvel") is pleased to announce that its rapid formulation screening program with Catalent, Inc., has identified a novel formulation of its lead asset MB-204.The formulation involves producing a solid amorphous dispersion of MB-204 using a simple, FDA approved excipient that has improved drug exposures by at least a factor of 20-fold. Improving oral bioavailability results in reduced amou
NewsfileMarvel Biosciences Closes First Tranche of Private Placement
Calgary, Alberta--(Newsfile Corp. - July 18, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to report that, further to its news release of June 21, 2022, it has closed the first tranche of its non-brokered private placement of 4,500,000 units of the Company (the "Units") at a price of $0.10 per Unit for gross proceeds of $450,000 (the "Offering"). Each ...